Dolutegravir in HIV patients with major depression in Nigeria
Treatments studied
Part of Mental health clinical trials.
This study looks at how the HIV medicine dolutegravir works in people who also have major depression. It aims to understand if depression affects how the drug stays in the body, and participants will also take an antidepressant (fluoxetine).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have HIV and be willing to take or continue HIV medication (dolutegravir).
- You need to have current symptoms of depression (feeling down, hopeless, etc.).
- You must be willing to take an antidepressant (fluoxetine) and attend scheduled visits.
- Your kidneys and liver must be working well (checked by blood tests).
- You cannot have certain conditions like bipolar disorder, psychosis, or recent drug abuse.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how depression and its treatment may affect the brain and immune-related body systems in people with HIV. You may be eligible if you have depression and a well-controlled HIV viral load, and you can safely complete brain MRI scans.
This Phase 2 study looks at whether lowering inflammation can help improve depression symptoms in adults living with HIV. You may be able to join if your HIV is well controlled and you are currently experiencing major depression (or a certain type of bipolar depression).
This study tests a program that helps people with HIV manage depression and stick to their treatment. It's for adults in Cape Town, South Africa, who have a detectable HIV viral load or may have one, and who show signs of depression.
This trial compares two HIV medications, dolutegravir and darunavir/cobicistat, to see which causes fewer brain-related side effects like sleep, mood, or anxiety issues. It is for adults starting HIV treatment for the first time.
This trial tests a two-drug HIV treatment (dolutegravir and lamivudine) for people who also have active TB and are taking a standard TB medicine called rifampin. It is designed for those who have not yet started HIV treatment.
This study tests if cognitive behavioral therapy (a type of talk therapy) can improve how your body handles sugar (insulin resistance) for people living with HIV who also have depression. You may join if you have HIV, are on stable HIV meds, feel depressed, and do not have diabetes.
Hear when a new Depression trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.